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Recently, theectopicexpressionofmyoglobin (MB)was reported inhumanepithelial cancercell linesandbreast
tumor tissues,whereMBexpression increasedwithhypoxia. Thebetter prognosis ofMB-positivebreast cancer
patientssuggested that theglobinexertsa tumor-suppressive role, possiblyby impairingmitochondrial activity
in hypoxic breast carcinoma cells. To better understandMB gene regulation in cancer, we systematically inves-
tigated the architecture of the humanMBgene, its transcripts and promoters. In silico analysis of transcriptome
data fromnormalhuman tissuesandcancer cell lines, followedbyRACE-PCRverification, revealed sevennovel
exons in theMB gene region, most of which are untranslated exons located 5′-upstream of the coding DNA se-
quence (CDS). Sixteen novel alternatively splicedMB transcripts were detected, most of which predominantly
occur in tumor tissue or cell lines. Quantitative RT–PCR analyses ofMB expression in surgical breast cancer
specimen confirmed the preferential usage of a hitherto unknown, tumor-associatedMB promoter, which was
functionally validated by luciferase reporter gene assays. In line with clinical observations of MB up-regulation
in avascular breast tumors, the novel cancer-associatedMB splice variants exhibited increased expression in
tumor cells subjected to experimental hypoxia. The novel gene regulatory mechanisms unveiled in this study
support the idea of a non-canonical role of MB during carcinogenesis.
INTRODUCTION
Myoglobin (MB) was the first oxygen-binding respiratory
protein described to appear in extravascular locations (1,2). It
ismainly expressed in skeletal and cardiacmuscle of vertebrates
at high micro- or millimolar concentrations (3–5). Owing to its
high O2-binding affinity (P50 1 Torr), MB supports the intra-
cellular diffusionofO2 from the sarcolemma to themitochondria
(6,5). In addition, MB functions in short-termO2 storage in con-
tractingmuscles for a steadier O2 supply to themitochondria (4).
Upon cellular hypoxia, MB has been described to decrease the
level of reactive oxidative stress and to detoxify harmful
excess nitric oxide (NO†) and nitrite (7–10).
MB expression was further reported in various human malig-
nant tumors and tumor cell lines that did not originate from myo-
cytic precursors, including acute leukemia, desmoplastic small
round cell tumors, breast carcinoma, colon carcinoma and non-
small cell lung cancer (11–15). In example, 40% of invasive
breast carcinomas were found to exhibit pronounced MB expres-
sion (14). Comparing MB levels in breast tumor biopsies and
healthy ductal tissue counterparts from the same individuals
revealedonaveragea350-foldhigherabundanceofMB transcripts
in the cancer tissues (14). In a corresponding Kaplan–Meier ana-
lysis, the overall survival of 917 primary breast cancer cases was
monitored and correlated to their MB and estrogen receptor
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alpha (ERa) status. Despite the fact that patients with ERa-
positive tumors generally have a better outcome, and that
mammary carcinomas displayed a tight association between the
presenceofMBandERa,we also documented the favorable prog-
nosis of ERa-deficient breast tumors with highMB content (ER-/
MB+) relative toERa-deficient/MB-deficient (ER-/MB-) entities
(14). Thus, MB is of prognostic value and might confer tumor-
suppressive activity in vivo.
To investigate the possible function ofMB in a tumor context,
lentiviral gene transfer was employed to overexpress mouseMb
in theMB-null A549 human lung cancer cell line (16). Resulting
experimental tumors expressing ectopic Mb displayed reduced
hypoxia, minimal levels of the O2-sensitive alpha subunit of
the hypoxia-inducible factor (HIF-1a), lower vessel density
along with a more differentiated cancer cell phenotype and
largely suppressed metastatic spreading. The authors correlated
these beneficial outcomes ofMb overexpression with the reduc-
tion of tumor hypoxia (16).However, this approach seems some-
what artificial, since the total amount of Mb in the engineered
cancer cells was similar to MB levels in human muscle [i.e.
(MB) 200–300 mM], while endogenously occurring MB
protein levels in breast cancer cells are several hundred-fold
lower (14). Therefore, it remains doubtful whether MB in
tumors is sufficiently abundant to confer meaningful O2 supply
capacity and to maintain aerobiosis in temporarily hypoxic
cancer cells. In line with a negligible role of endogenous MB
in O2 transport in breast tumor cells, high-resolution respirome-
try on stableMB knockdown clones of suspendedMDA-MB468
breast cancer cells revealed, when compared withMB proficient
controls, statistically indistinguishable in vitro P50(O2) values
(17). Apparently, endogenous MB in breast tumors and breast
cancer cells may thus exert a non-classical molecular function.
Along this line, it has been proposed thatMBmay regulate oxida-
tive/nitrosative stress incancer cells, e.g.by its ability toscavenge
toxic NO† under hypoxic conditions (13). Our own experiments
using siRNA-drivenMB silencing inMDA-MB468breast cancer
cells indicated that MB interferes with the capacity of the mito-
chondria specifically in hypoxic carcinoma cells. MB was add-
itionally found to influence proliferation and motility of these
cells, yet in ways not directly related to the facilitated diffusion
or storage of O2 (17).
The attractive hypothesis that MB might have tumor-
suppressive properties raised the question for the gene regulatory
mechanismsdriving the transcriptionof theglobin incancercells.
MB immunostaining on breast ductal carcinoma in situ (DCIS)
entities revealed a gradient of MB expression, which correlated
with hypoxia markers (17). Several publications also reported
the robust increase of MB concentrations by transcriptional
up-regulation in epithelial cancer cells subjected to hypoxia
(13–15).Analogous to the functional discrepancies between car-
cinoma and myocytic MB, this hypoxia-mediated increase in
cancer MB expression is also at odds with known regulatory
mechanisms of MB in muscles. According to the current view,
hypoxia acts only as an effective regulatory stimulus ofMB ex-
pression in muscle when it is accompanied by other triggers
(such as exercise) (18). This observation is concordant with the
fact that the standard muscle MB promoter region apparently
lacks canonical HIF-binding cis-elements (i.e. hypoxia response
elements, HREs) and hypoxia inducibility (19). Recently,
however, one alternative MB transcript (NM_203377) was
reported to originate from a different, non-standard promoter
site, which appeared predominantly active in the breast cancer
cell line MDA-MB468 (17). This alternative MB mRNA was
300-fold increased over the standard transcript in the breast
cancer cell line. Moreover, the alternative mRNA was 2.2-fold
induced in cells challenged by prolonged hypoxia, compared
with normoxic samples. However, it remained unclear whether
the novel transcript occurs also in clinical specimen in vivo or
in other cell lines. In addition, a novel candidate HRE, located
2.8 kb upstream of the translation start site of theMB gene was
identified, which enhanced reporter gene transcription by
43% in hypoxic MDA-MB468 cells. Apparently, this
element is therefore only a minor contributor to hypoxicMB in-
duction (17).
In the present study, we systematically characterized the
spectrumofMB transcriptvariants and their initiationsitesby tran-
scriptome sequence data mining and experimental verification.
We evaluated the expression levels of novel, alternative MB
transcripts in various human tissues and cancer cell lines by the
quantification of RNA-Seq data. To account for mouse as a
model organism, we examined conservation of the human and
mouseMb gene structures. Expression rates ofMB transcript var-
iants were compared in normoxic and hypoxic cultures of a breast
and a colon cancer cell line to elucidate howdiminishedO2 supply
impacts onMB gene regulation in different cancer backgrounds.
The biological relevance of cancer-associated, hypoxia-inducible
MB transcripts was then validated in breast cancer biopsies, and
the functionality of a novel promoter was studied by dual lucifer-
ase reporter assays (DLRAs). To identify functional differences
between the cancer-linked MB transcript variants, the influence
of an alternatively spliced upstream open reading frame (uORF)
on globin translation efficiency was examined.
RESULTS
A revised structure of the humanMB gene
To identify the full spectrum of alternative transcripts from the
human MB gene, we first mined available MB transcriptome
data from the NCBI UniGene EST (expressed sequence tag)
database (for a list of representative ESTs supporting alternative
MB transcripts, see Supplementary Material, Table S1). RT–
PCR reactions using cDNA from the breast and colon cancer
cell linesMDA-MB468 andDLD-1, respectively,were thenper-
formed to verify the in silico-predicted utilization of MB exon
sequences (Supplementary Material, Table S2). Amplicons
were sequenced to assemble a list of novel exons and splice var-
iants of the humanMB gene (Supplementary Material, Fig. S1,
Fig. 1). EST and RT–PCR data from cancer cells revealed six
novel exons located within the 5′UTR (untranslated region) of
the human MB gene and one alternative non-coding start exon
located between the first and the second coding DNA sequence
(CDS)-containing exon (Fig. 1). Considering all known and
newly annotated exons, the genomic sequence of human MB
now encompasses 31 796 bp (coordinates in genome build 37/
hg19 are q12.3 Chr 22: 36 002 811–36 034 607), thus about
doubling the size of the current human MB gene annotation in
the NCBI database (Supplementary Material, Fig. S1 and
Fig. 1). Exons were numbered in 5′ . 3′-direction, tagging un-
translated exons with a ‘u’ and exons that encode at least part
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of the CDS, with a ‘c’. The three long-known CDS-containing
exons 1–3 were thus renamed as exons 9 c, 11 c and 12 c, re-
spectively (20).
From the newly detected exons,wewere able to infer 16 novel
splice variants in addition to three previously annotated ones
(Supplementary Material, Fig. S1). Variant 2 corresponds to
the NCBI-annotated transcript NM_005368.2 (AceView tran-
script b) and the first published MB structure (20). Variant 13
equals NM_203377.1 [AceView transcript d; also see (17)]
and variant 5 has been annotated as NM_203378.1 (AceView
transcript c). According to EST data, these previously annotated
transcripts are themost commonones. TheCDS-encoding exons
11 c and 12 c were present in all known and novel splice forms,
andmost variants also contained exon9 cwith the canonical start
codon. Thus, 9 out of 19 transcript variants encode the standard
MB protein as found in muscle, whereas all others translate into
either noor a truncatedMBprotein.All introns are equippedwith
consensus splice sites.
The integrity of the novel protein-encoding MB transcripts
was confirmed via 5′ and 3′RACE, using total RNA from the
MDA-MB468 cell line. In the case of transcript variants 9, 10
and 11, the sequences resulting from 5′RACE reactions sug-
gested the first exon (exon 5 u) to start 25 bp upstream of the
MB transcript version annotated by AceView. The splice
variant 13, starting with exon 4 u, was identified to contain an
additional 15 bp when compared with the AceView annotation.
We further approved the integrity of variant 19, starting at exon
1 u, via 5′ RACE (Supplementary Material, Fig. S1).
Phylogenetic conservation of theMB gene
A search for evolutionary conserved regions within theMB gene
was conducted to reveal stretches of most important biological
function. BLASTN pairwise local alignments of human MB
and the respective gene regions from other species (Supplemen-
tary Material, Table S3) showed that exon 9 c displays the
highest sequence conservation. This conservation ranged from
100 to 76% identity to MB of chimp and chicken, respectively.
The other CDS-encoding exons 11 c and 12 c were also highly
conserved in mammals and birds with percent identities ranging
from99 to70%.Regarding thenon-coding5′UTR, thealignments
showed a gradual exon conservation between vertebrate species
(Supplementary Material, Table S3). Exons located proximal to
the CDS of the globin (such as 8 u) tended to show higher conser-
vation thandistant exons, suggestinga lower selectionpressureon
the 5′region of theMB gene in evolution.
Owing to the importance of mouse (Mus musculus) as the
prime mammalian model organism for biomedical research, a
comparison of human and mouse Mb gene structures (coordi-
nates in mouse genome build 38/mm10 are qD3 Chr15:77 015
487–77 050 668) for synteny was of particular interest. For
this, allmouse ESTs available onNCBIUnigenewere annotated
in terms of exon presence and tissue type. Equivalent to the
human MB gene, mouse Mb exons were renamed numerically
in 5′ . 3′ orientation. Two novel upstream exons and four add-
itional splice variants were detected in mouse (Supplementary
Material, Fig. S2b). However, conservation among vertebrates
turned out to be very limited: all CDS-containing exons and
human exon 8 u, equivalent to exon 4 u in mice (Supplementary
Material, Fig. S2b) showed the (expected) sequence conserva-
tion, whereas all other human and mouse Mb upstream non-
coding exons were not alignable and are thus not conserved
between the two taxa (Supplementary Material, Fig. S2a). A
reason might be that 56% of the genomic area encompassing
the 5′UTR of human MB consist of repetitive elements, such
as Alu and L1 elements typical for primate genomes (Supple-
mentary Material, Fig. S3).
Tissue-specific expression ofMB transcript variants
To identify tissue-specific MB splicing patterns, all ESTs (n ¼
972) were assigned to their tissues of origin (Supplementary
Figure 1.Revised exon-intron structure of the humanMB gene and its former version (top). Exons are shown as dark boxes with their sizes in bp written on top. Un-
translated andCDS-encoding exons are taggedwith a ‘u’ or ‘c’, respectively. Themost prominent protein encoding splice variants frommuscle (variants 2 and 5) and
from cancer-related samples (variants 9–11, 13) are shown, including the start and stop codons of theMB-CDS.
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Material, Fig. S1). Expectedly, the standard MB transcript
(variant 2), represented by 557 ESTs, was most prominently
seen in skeletal and heart muscle, and to a much lesser extent
in smooth muscle tissues. At least 8 of the 16 novel transcripts
were also expressed in muscle tissues, but are only represented
by very few EST reads (n ¼ 13). Fifteen EST entries, corre-
sponding to eight MB transcript variants, were observed in
data sets from a large variety of non-muscular tissues, including
liver, lung, prostate, testis and sciatic nerve (SupplementaryMa-
terial, Fig. S1). In cancer cell lines, EST analysis (n ¼ 8 reads)
and RT–PCR experiments demonstrated the presence of 12
out of the 19 MB splice variants. As suggested by our previous
study (17) and now confirmed by EST data, transcript variant
13 appeared to be one of the major transcripts expressed in
cancer cell lines. In addition, three other protein-codingMB tran-
scripts were found in the breast and colon cancer cell lines, i.e.
variants 9 (AceView transcript a), 10 and11 (AceView transcript
f), which all have a common transcriptional start at exon 5 u
(Fig. 1). The MB-coding variant 19 was only detectable in
MDA-MB468 cells, but missing in DLD-1 cells.
To infer relative expression profiles of different body tissues
and cancer cell lines, we additionally analyzed 41 RNA-Seq
data sets from MB expressing human tissues and cancer cell
lines (Supplementary Material, Table S4). Sequence reads
were mapped against the human MB CDS-containing exons
and the 5′UTR starting exons, quantified and normalized. Tran-
scription of MB-CDS encoding exons was on average 25-fold
and 333-fold higher in heart muscle than in normal breast and
colon tissue, respectively (Fig. 2). We noted that the mRNA ex-
pressionmeasured inbreast tissues appearedhigher than expected
fromprotein studies (14), andmight thereforebepartlydue tocon-
taminationwithmyocytes. In the cancer cell lines,MDA-MB468,
MCF-7, LNCaP and DLD-1, average CDS-exon expression was
115-fold lower than in heart tissue (Fig. 2).
In addition, great differences were noted in the utilization fre-
quency of the alternative 5′UTR starting exons among the inves-
tigated data sets. As expected from our EST analyses, starting
exons 8 u and 9 u are predominantly used in muscle and heart,
whereas upstream exons 4 u and 5 u are distinctly under-
represented in non-cancerous tissues (Fig. 2). For instance, in
human heart those transcripts starting at exon 9 u are 800
times more abundant than those starting with exon 5 u (Fig. 2).
In contrast, cancer cell lines such as MB468, DLD-1 and
LNCaP as well as prostate tumor biopsies only expressMB tran-
scripts starting at upstream exons 4 u and 5 u, yielding mRNA
variants 9, 10, 11 and 13 (Supplementary Material, Fig. S1).
Since there were no reads mapping to the start exons 1 u, 2 u
and 10 u in all analyzed transcriptomes, we do not expect their
associatedMB transcripts to typically appear in cancer cells.
Quantification ofMB transcript variants in cancer cell lines
In silico analyses of RNA-Seq data sets (Supplementary Mater-
ial, Table S4) and analyses of cDNAs from MDA-MB468 and
DLD-1 cells using exon junction-spanning primers to specifical-
ly distinguish between splice variants revealed that the protein-
codingMBmRNAvariants 9, 10, 11 and 13 are present in cancer
cell lines. Therefore, these mRNAs might be crucial for the ex-
pression of functional MB in tumor tissues. Based on this idea,
we quantified the expression of these MB transcripts in
MDA-MB468cells and inDLD-1cells viaquantitative real-time
reverse-transcriptase PCR (qRT–PCR). Compared with the
standard muscle transcript (variant 2), normoxic MDA-MB468
cells produced 374–708-fold higher quantities of the alternative
MB transcript variants 9, 10 and 11 (Fig. 3). Even transcript
variant 13 is significantly more strongly expressed than variant
2 in the breast cancer cell line, although it accounts for only
2% of all transcripts in MDA-MB468 cells. Since the amount
of splice variants 9, 10 and 11 greatly exceeded that of variant
2 also in the colon cancer cell line DLD-1, these mRNAs
appear to dominate the transcriptional profile of MB in a more
widespread fashion in epithelial cancer cells.
Hypoxia induction ofMB transcripts in cancer cell lines
Our previous work pointed to tissue hypoxia as a contributing
stimulus of MB expression in DCIS entities (17). We also
noted that transcripts corresponding to the cancer-associated
MB splice variant 13 (starting with exon 4 u) were 2.2-fold
up-regulated in MDA-MB468 cells subjected to 1% O2 for 72 h
(17). Equivalent to those experiments, we now compared the
abundance of novel, protein-coding cancer-associated MB
splice forms among the cDNA samples of MDA-MB468 cells
and DLD-1 cells raised under hypoxic (72 h, 1% O2) and nor-
moxic (72 h, air) conditions via qRT–PCR.Relative tonormoxic
oxygen supply, transcripts variants 9, 10 and 11 showed a statis-
tically significant 3- to 3.5-fold increase in MDA-MB468 and a
1.5- to 2.1-fold up-regulated expression in DLD-1 cells in re-
sponse to oxygen deprivation (Fig. 3). As a result, splice variants
9, 10 and 11 (all transcribed from exon 5 u) most likely underlie
the hypoxia-mediated increase ofMB in breast and colon cancer
cell lines [see (17) for western blot evidence].
Detection ofMB transcript variants in breast cancer tissues
To prove the relevance of alternativeMB transcripts in clinically
relevant human breast cancer specimens,we also investigated bi-
opsies of 21 breast cancer patients. Following surgical resection
of the tumors, tissue specimenswere first tested forMBpositivity
by immunostaining. After RNA extraction and cDNA synthesis,
the four protein-encoding MB splice forms most commonly
found in cancer cell lines and the standard transcript variant 2
were quantified by qRT–PCRs in each tumor sample. In line
with our in vitro data of breast and colon cancer cell lines, the
MB transcripts 9, 10 and 11 also represented the dominant MB
mRNA fraction in the breast cancer cases (Fig. 4A). Compared
with the sumof variants 9, 10 and11, expressionof theMB stand-
ard transcript variant 2 was on average 14-fold suppressed in
tumors. The vast majority of the cancer cases expressed variant
9 at maximal quantities, followed by variant 11 and variant 10.
In conclusion, the promoter upstream to their common start
exon 5 u is the most active driver of MB transcription in breast
tumors, while the muscle-associated standard promoter most
likelyplaysonlyaminor role.TheMB splicevariant13,previous-
ly described in the breast cancer cell lineMDA-MB468 (17),was
weakly expressed in tumor specimens. Compared with the
26-fold more abundantly present variants 9, 10 and 11
(Fig. 4A), variant 13 is probably of minor importance in an
in vivo context.
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Hypoxia inducibility ofMB transcripts in breast
cancer tissues
We have shown so far that the novelMB transcript variants 9, 10
and 11 are inducible in hypoxic cancer cell lines. In addition,
variant 13 was earlier reported to be up-regulable in breast
cancer cells upon challengewith 1%O2 (17). To correlate the ex-
pression ofMB transcripts with the degree of hypoxia in tumor
tissues, we further quantified mRNA levels of the
hypoxia-specific biomarker vascular endothelial growth factor
A (VEGFA) by qRT–PCR. A significant positive Pearson’s cor-
relation between VEGFAmRNA increase upon hypoxia stimuli
and enhanced expression of the MB variants 9, 10, 11 (P,
0.001) and variant 13 (P , 0.001) under hypoxia was found.
In addition, the hypoxia induction of MB variant 13 correlated
strongly and positivelywith the hypoxia response of the variants
9, 10 and 11 (Pearson, P , 0.001). However, no significant cor-
relation was found between the response of MB variant 2 to
hypoxia and the hypoxia inducibility of VEGFA (P ¼ 0.7).
In addition, the degree of hypoxic stress was also inferred by
performing carbonic anhydrase IX (CAIX) antibody staining in
tumor tissue sections adjacent to the ones used for RNA prepar-
ation, as the HIF-1a/-2a target gene CAIX is a widely used
marker of local tissue hypoxia in solid malignancies. Most
tumors with strong MB transcription were also CAIX positive
(Fig. 4B), with few cases showing a discrepant result (i.e.
sample D). For a biological interpretation, one should take into
account that hypoxia is considered a local phenomenon, where
totally different O2 levels may occur in adjacent tissue sections.
Identification of a novel, activeMB promoter in cancer cells
As described above, in the cancer cell lines MDA-MB 468 and
DLD-1 theMB mRNA variants 9, 10 and 11 are all transcribed
from the same start site, the 5′end of exon 5 u. To characterize
the novel gene regulatory region upstream of exon 5 u, we
utilized the program Gene2Promoter to identify a 638 bp se-
quence fragment (Genomatix promotor identification number
GXP_2244649; see Fig. 5) as a candidate active promoter
sequence. Next, different regions of the predicted promoter se-
quencewere cloned into luciferase reporter vectors to investigate
their transcriptional activity in transfected MDA-MB468 cells.
The quantified light units of each plasmid were normalized to
light intensities of empty vector controls. The largest candidate
fragment (692 bp), ranging from 501 bp upstream of the to
191 bp downstream of the transcription start site, was active in
breast cancer cells with a 23-fold increase in relative light units
(RLUs), when compared with the control (Fig. 5). This fragment
fully encompassed theGene2Promoter-predictedGXP_2244649
sequence. To further characterize transcriptional activities along
the promoter region, progressive deletions of the 692 bp region
from its 5′ and3′endsweremade and compared in their luciferase
readouts to the full-length fragment. Regions containing up to
179 bp upstream to the transcription start site were as active as
Figure2.Quantification ofMB start exon transcription in different human tissues
by RNA-Seq read counting. Normalized RPKM values [reads per exon size (in
kb) per total reads of the data set (in Mio)] indicate the transcriptional represen-
tation of preferential start exon and CDS-containing exons.
Figure 3.Expression analysis ofMB splice variants in vitro in normoxic and hypoxicMDA-MB468 breast cancer andDLD-1 colon cancer cells. Numbers in the left
half of the table show cDNA copy numbers determined by qRT–PCR, fold-changes in the right half of the table indicate hypoxic up-regulation (∗P , 0.05; ∗∗P ,
0.01; ∗∗∗P , 0.001; n ¼ 3). Primerswhich are able to distinguish between transcript variants 2, 9–11 and 13, are indicated by arrows above (forward) and underneath
(reverse) their respective target exons.The solid, dashedanddotted lines that framefieldsof the table indicatepromoters commonbetween the splice forms (also shown
left to each transcript variant’s graph).
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the complete 692 bp fragment in MDA-MB468 cells (i.e.
50-fold increased reporter gene activity), whereas DNA sec-
tions containing only 108 bp upstream of the transcription start
site showed much weaker promoter activity (Fig. 5). At the
3′end, DNA sections that ended 25 bp downstream of the tran-
scriptionstart site conferred the strongest reporter gene activation
(i.e.40-fold increase ofRLUs). In contrast, constructs that con-
tained only up to 17 bp downstream of the transcription start site
triggered only a 22-fold increase in RLUs (Fig. 5). In result, the
most active promoter region upstream of exon 5 u consists of a
204 bp fragment that at least starts 179 bp upstream and ends
25 bp downstream of the transcription start site. A ConSite
search for common cis-acting promoter elements revealed a
CCAAT-box motif (NF-Y) proximate (57 bp upstream) to the
transcription start site (seeFig. 5) that contains a perfectlymatch-
ing pentanucleotide motif. Owing to its position within the
204 bp fragment, this site might be relevant for promoting the
transcription of cancer-associatedMBmRNAs.
An additional open reading frame within the
humanMB gene
Among theprotein-codingMB transcripts, variant 11 is unique in
containing exon 7 u, which is located on an Alu element. This
exon encodes a potential 78 bp uORF, starting at its first
basepair. uORFs usually do not encode functional proteins but
control the translation efficiency of the following protein
coding sequence by facilitating ribosome dissociation (21,22).
To test the functionality of the uORF in exon 7 u, pGL3-control
reporter assay plasmids were constructed that contain either the
full uORF or a point-mutated version (c.-3067A . T, resulting
in TTG instead of ATG as a start codon). Neither the uORF,
nor its point-mutated version contained a second, additional
ATG.Tomirror thenatural degree of ribosome reinitiation as oc-
curring on theMBmRNAvariant 11, the exact basepair compos-
ition that stretches between the uORF and the MB-ORF was
added to both plasmids upstream to their luciferase-ATGs.
Both constructs were co-transfected with pGL4.74 vectors in
MDA-MB468 cells and quantified by DLRAs. Since the unmu-
tated construct containing the uORF (ATG) conferred a 34%de-
crease in reporter gene translation efficiency relative to the
mutated uORF (TTG) construct (Fig. 6), the candidate uORF
is indeed able to significantly impair the ribosome attachment
upon translation of theMB CDS in transcript variant 11.
DISCUSSION
Although MB is traditionally regarded as one of the best-
characterized proteins in biochemistry, advances in recent
Figure 4. (A) Expression analysis ofMB splice variants in breast cancer biopsies (namedA to U). cDNA copy numbers (per 10 ng cDNA) inferred by qRT–PCR are
plotted on the y-axis (bars). Values for variants 9–11 have been summed up and are shown relative to expression of theminor cancer-associated transcript 13 and the
muscle-typic variant 2. (B) Correlation betweenMB expression and hypoxiamarkers in breast tumor specimen. The fold-increase ofMB variants andVEGFAmRNA
expression (bars) in tumors versus normal tissue, inferred by qRT–PCR, is shown in relation to the intensity of CAIX immunostaining, as applied to the same tumor
sections.
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years have revealed several novel, additional functions of this
protein inNO† andROS (reactive oxygen species)metabolisms,
thereby extending its classic role in O2 supply to muscle cells
(5,7,8,23). In parallel, it was shown that beyond its primary
localization in cardiac myocytes, skeletal and smooth muscle
(3–5,24), MB is expressed at several ‘ectopic’ sites. Important-
ly, these additional expression sites include breast cancer,
non-small cell lung cancer, colon and ovary carcinomas, desmo-
plastic small round cell tumors and leukemic bone marrow, as
well as derived breast, colon and osteosarcoma cancer cell
lines (11–15), and also luminal cells of healthy breast tissue
(14).Fromazoological perspective, thesedatamaynotbe entire-
ly surprising since, e.g. in the commoncarp, small amounts of the
globin were detected in various non-muscle tissues, including
liver, gill, kidney and brain (25). The biological function of
ectopic MB expression, however, has remained elusive up till
now. In the present study, data mining of publicly available
RNA-seq data sets have confirmed transcription of MB in
several healthy and tumorous human tissues and cancer cell
lines at mRNA levels corresponding to roughly 1/100 of the
amount present in heart muscle (Fig. 2). Most importantly,
detailed analyses ofMB transcription revealed that the organiza-
tion, splicing patterns and promoter usage of the MB gene are
also muchmore complicated and variable than hitherto thought.
Unexpected complexity of theMB gene and its transcripts
Our EST and RNA-Seq data analyses revealed 11 alternativeMB
protein-coding transcripts in human tissues, themajority ofwhich
has been hitherto undescribed (SupplementaryMaterial, Fig. S1).
Figure 5. Functional analysis of the promoter section upstream of exon 5 u. DLRAswere conducted on promoter sections that were PCR-amplified from primer sites
represented by black arrows. The numbers on the arrows indicate the bp distance to the transcription start site of theMB splice variants 9–11. An in silico-predicted
promoter region and a commonly observed cis-acting promoter element (NF-Y box) are indicated. The average RLUs of each construct were plotted in the bar chart;
standard deviations are indicated by error bars (∗P , 0.05; ∗∗∗P , 0.001; n ¼ 3).
Figure 6. Functional analysis of a uORF inMB cassette exon 7 u. DLRA results,
plotted as a bar chart, show translational activity of the uORF-containing con-
struct (ATG)and its point-mutatedversionTTG(c.-3067A. T) for comparison.
Standard deviations are indicated by error bars (∗∗∗P , 0.001; n ¼ 5).
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An additional eight transcripts, producing aberrant or truncated
MB versions, could be detected. However, their frameshift-
inducedpremature stopcodons in theMB-CDSarepositioneddis-
tantly upstream of the distal 3′ splice site, making it likely that
RNA-decay mechanisms (reviewed in: 26) degrade these tran-
scripts prior to translation. This bewildering complexity of MB
transcript variants is due to the presence of several novel exons
within a substantially enlarged MB gene region of 31.8 kb
instead of its former size of 16.6 kb. TheMB gene thus illustrates
results of the ENCODE project, stating that roughly 75% of the
human genome is primarily transcribed (27). ENCODE cell
lines were reported to express on average sets of 10–12 mRNA
isoforms per gene, which agrees well with the expression of 9
and 6 alternativeMB transcripts (out of 19 splice forms in total)
in human skeletal and heart muscle, respectively. In cancer cell
lines, 12 out of the 19MBmRNAvariantswere detected (Supple-
mentary Material, Fig. S1). Three of those variants, all hitherto
undescribed, were most frequently observed in breast cancer en-
tities, andonebreast andonecoloncancer cell line (Figs 3and4a).
Thus, MB expression also adheres to the ENCODE rule that
mostly one isoform per gene is predominantly expressed upon a
certain cellular condition, and that 75% of all genes produce at
least two major transcripts (27).
The obvious question for the adaptive functional value ofmul-
tiple MB splice forms cannot be fully answered to date, but the
observed transcriptional complexity is clearly contradictory to
a ‘minimalistic expression strategy’ (27,28). As a possible
example for the functionality of upstream exons, we found that
the alternatively spliced cassette-exon 7 u is able to decrease
MB translation efficiency via its part encoding a uORF (Fig. 6).
Owing to the fact that the mRNA section between the uORF
and the downstream MB-ORF is rather short (49 bp) and does
not contain internal ribosome entry sites, we speculate that ribo-
some re-initiation is likely to be hindered to some extent when
exon 7 u is spliced in (21,22,29,30). While the recorded effect
on translation appears rather moderate in vitro, a non-linearity
between MB protein and mRNA levels in a breast cancer cell
line, possibly indicating post-transcriptional effects, has been
reported previously (13). Notably, cassette-exon 7 u is part of
anAluSc family element thatwas inserted into theMBgene, illus-
trating thepotentially adaptive effect of retrotransposons asmod-
ulators of gene regulation during primate evolution (31–33).
Various primate-associated transposons such as Alu and L1 ele-
ments have invaded the 5′ part of the human MB gene region
(Supplementary Material, Fig. S3). Not surprisingly therefore,
the novel MB upstream exons are only conserved throughout
higher primate orders (Supplementary Material, Table S3) and
lack orthologues in themouseMb gene, which displays less vari-
ability on the genomic level and in its splice patterns. Studying
transcriptional regulation of ectopic Mb expression in the
mouse may therefore be of limited value.
Most important to understand the gene regulatorymechanisms
driving classic and ectopicMB expression is the fact that the alter-
native usage of 5′ upstream exons implies the existence of differ-
ent promoters for the MB gene. For instance, MB transcript
variants 2 and 5 are the most abundant mRNAs in heart and skel-
etal muscle (Fig. 2), but only variant 2 starts downstream of the
classical TATA box motif (20). Interestingly, despite extensive
work on this promoter region,which has led, e.g. to the identifica-
tion of functionally relevantMEF2, Sp1 and NFAT transcription
factor binding sites (34), the presence of an alternative transcrip-
tional start site 5′ of starting exon 8 u has escaped notice so far, al-
though it originates between the twoNRE-elements and therefore
covers the conventional promoter region. For themost activeMB
transcriptional start site in cancer cells, our reporter assays con-
firmed a 204 bp promoter section upstream of exon 5 u to
confer high transcriptional activity in the MB expressing breast
cancer cell line MDA-MB468. This section contains an integer
CCAAT-box (also known as NF-Y), a motif that is often used
to facilitate the transcription of genes over-represented in
cancer (35). Furthermolecular studies are necessary to character-
ize the relevant gene regulatory elements of this tumor-associated
MB promoter beyond mere bioinformatic predictions.
Cancer-associated humanMB splice variants
are hypoxia-regulated
Theexistenceof additional promoter regions in theMBgenemay
clearly have the adaptive value of facilitating gene expression
under special circumstances. From the viewpoint of tumor
biology, it is an important finding that the MB transcripts
initiated by the novel exon 5 u promoter (variants 9, 10, 11)
are distinctly up-regulated by hypoxia, a frequentmicroenviron-
mental influence determining tumor physiology andmalignancy
(36,37; see discussion below). A 1.5–3.5 fold induction of those
MBmRNAs was demonstrated in vitro in the breast cancer cell
lineMDA-MB468 and inDLD-1 colon cancer cells upon experi-
mental hypoxia. In breast cancer biopsies, MB transcriptional
up-regulation was paralleled by increased mRNA expression
of the hypoxia-responsive VEGFA gene and on the protein
level by positive immunostaining of the hypoxia-marker
CAIX, suggesting that MB up-regulation at lowered oxygen
levels also occurs in vivo. In line with these observations, we
had previously reported (17) that another minor MB transcript
(variant 13) also showed hypoxia-sensitivity (at 1% O2) in
MDA-MB468 breast cancer cells (but not in colon-derived
DLD-1). Also, MB immunostaining distribution correlated
with local tissue hypoxia in many cases of DCIS cancer entities,
which originate in the breasts’ avascular milk ducts and com-
pletely rely ondiffusionalO2 and nutrient supply, thus becoming
more andmore hypoxic towards their center during growth (17).
The degree of hypoxia-responsivity of the MB gene in the
classic context of muscle cells has been a debated issue (38–
42). Recent work showed that while the Mb content of the con-
tracting heart of mice increased under moderate hypoxia (10%
O2), mouse Mb remained unchanged in sedated skeletal muscle
(18). However, MB transcription in skeletal muscle could be
induced by exercise via Ca2+ ion release to activate the calci-
neurin/NFAT pathway, with an increased calcineurin sensitivity
upon hypoxia (18). Thus, at least in skeletal muscle,MB regula-
tiondoesnot respond toan isolatedhypoxic stimulus, but requires
a combination of exercise and hypoxia (reviewed in 34,43). In
line with this finding, the muscle-associated standard MB pro-
moter was reported to lack canonical binding sites for the
hypoxia-responsive master transcription factors HIF-1a/-2a
(19,18). In contrast, we have recently identified a candidate
HRE within the upstream region of theMB gene that conferred
amoderate 43%hypoxia induction toadownstream luciferase re-
porter gene (17). It is therefore probable that this HRE alongwith
other, hitherto uncharacterized enhancer sites drives the
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hypoxia-inducible transcription ofMBmRNA variants in cancer
cells. The recruitment of novel upstream exons and promoters in
the primate lineage thus has facilitated evolution of an additional
regulatory potential, which enables MB expression under
hypoxic cellular stress. This potential appears to be specifically
realized in a tumor context. It remains unclear, however, why a
minor usageof the non-standardMB splice forms is also recorded
in non-cancerous tissues, as observed in healthy breast, skeletal
and heart muscle (comp. Fig. 2).
A non-standard molecular function of MB in hypoxic
tumor tissues?
Atcurrent, thebiochemical functionof ectopically expressedMB
inmammals is unclear.MBprotein levels in breast tumor cells as
well as inhealthybreast tissue appearmuch too lowto account for
a respiratory function, suggesting a non-standard function ofMB
in tumor cells (17,44). This is even more likely, as work in myo-
cytes has revealed important additional roles ofMB, e.g. in com-
pensating oxidative and nitrosative stress (7–10). In hypoxic
tumor areas, an induction of (low-level) MB expression might
interfere with the homeostasis between formation and sequestra-
tion ofROS andRNS (reactive nitrogen species), and subsequent
biochemical studies will have to address these functional scen-
arios. Most importantly, MB-positive tumors reflect the
luminal, better differentiated carcinoma phenotype along with
an ameliorated prognosis for the patient, possibly due to
advanced cell differentiation, less aggressiveness and reduced
metastatic spread (13,14,16). Recent experiments onMB knock-
down MDA-MB468 breast cancer cells indeed indicated that
MB—byunknownmechanisms—impairsmitochondrial activity
under hypoxia (17). MB therefore harbors the potential of acting
as a tumor-suppressor, and its hypoxia-responsive up-regulation
may partly explain its beneficial effect on breast tumor patients’
survival.
MATERIALS ANDMETHODS
Bioinformatic analyses of theMB gene region
To elucidate the human andmouseMB/Mb gene structures, their
corresponding EST files were downloaded fromNCBIUniGene
(http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?UGID=908333
&TAXID=9606&SEARCH=mb, last accesseddate onSeptember
24, 2013) andaligned to thegenomicMB sequenceusing theNCBI
Spidey software (45). Novel exon regions and splice variants were
portrayed with GenePalette 1.2 (46). All new splice variants were
cross-checked with the transcripts available at NCBI AceView
(http://www.ncbi.nlm.nih.gov/ieb/research/acembly/, last accessed
date on September 24, 2013) and annotated, if amatching sequence
has been found. We applied Gene2Promoter (www.genomatix.de,
last accessed date on September 24, 2013) to predict the promoter
sequences of novel 5′UTR splice variants (47). Common cis-acting
promoter elements (TATA,CCAAT andGCboxes) were searched
within the experimentally validated cancer-active MB promoter
(Fig. 5) with ConSite (http://www.phylofoot.org/consite/, last
accessed date on September 24, 2013), choosing aminimum speci-
ficity of 12 bits and aTF cut-off of 82%.All detected elementswere
then checked for the integrity of their essential coremotif sites. The
revised gene structures of humanMB andmouseMbwere depicted
with SeqBuilder (Lasergene Sequence Analysis Software,
DNASTAR, Inc., USA). The positions of repeats relative to the
newly identified exons were determined by RepeatMasker (http://
www.repeatmasker.org, last accessed date on September 24,
2013) (48) and outlined on the human MB gene by SeqBuilder.
All novel MB splice variants were inspected for encoded ORFs
with EditSeq (Lasergene Sequence Analysis Software,
DNASTAR, Inc., USA). Additionally, NCBI-BLASTX (49)
searches were performed to reveal whether novel exons and exon
combinations had protein coding potential. The phylogenetic con-
servation of newly found humanMB exons was assessed in NCBI-
BLASTN searches against the respective genes (plus a flanking
50 kb frame) of Pan troglodytes (2.1.4), Macaca mulatta
(051 212), Callithrix jacchus (3.2), Canis familiaris (3.1), Bos
taurus (UMD3.1), Mus musculus (GRCm38.p1), and Gallus
gallus (4.0).Only hits with an e-value of E, 1–10 were listed.
For an extended de novo detection ofMB in different human
tissues, high-throughput RNA-Seq data sets of different human
tissues and cancer cell lineswere downloaded from theNCBISe-
quence Read Archive (SRA; see SupplementaryMaterial, Table
S4). All data sets were mapped against the genomic sequence of
theMB gene (chromosome 22 of the human genome built 37) by
applying the Tophat program package (http://tophat.cbcb.umd.
edu/, last accessed date on September 24, 2013) with a
maximum of two mismatches (default settings). To quantify
MB exon usage in the different transcriptomes (Supplementary
Material, Table S4) reads mapping to the coordinates of each
MB transcript start exon (4 u, 5 u, 8 u, 9 u) and CDS-containing
exons (9 c, 11 c and 12 c) were counted and normalized relative
to the according exon and data set size to generate RPKM-values
[reads per exon size (in kb) per 1Mio. reads of the dataset]; (50).
Dependent of the availability of tissue data sets on the SRA,
average ratioswere calculatedviaExcel 2003 (Microsoft) ifmul-
tiple data sets per tissue type were used.
Characterization ofMB splice variants in cancer cell lines
The breast cancer line MDA-MB468 and the colorectal adeno-
carcinoma cell line DLD-1 were cultured in DMEM/Hams-F12
with stable glutamine (PAA), supplemented with 10% FBS
Gold (PAA) and 1%Pen/Strep (PAA). For normoxic culture con-
ditions, cells were raised in an IG150 incubator (Jouan) at 5%
CO2 in an H2O-saturated atmosphere at 378C. For experimental
hypoxia, cells were raised in a CB 53 incubator (Binder) in an
H2O-saturated atmosphere at 378C, 1% O2 and 5% CO2.
To experimentally verify novel splice variants, totalRNAwas
extracted from cell lines by applying the RNeasy Mini Kit
(Qiagen), including aDNase I digestion. First-strand cDNAsyn-
thesiswas carried out on 1 mg of total RNAusing the Superscript
III RT- Kit (Invitrogen). 5′/3′ RACE reactions were performed
on RNA from MDA-MB468 cells using the Gene Racer Kit
(Invitrogen). RT–PCRs on cDNA were conducted with the
TrueStart Taq DNA Polymerase kit (Fermentas) in a peqSTAR
96 Universal Gradient Thermocycler (Peqlab) or T3 Thermocy-
cler (Biometra), according to the manufacturer’s instructions.
Annealing temperatures were chosen in accordance with the
melting temperatures of the primer sets. PCR amplicons were
purified by the High Pure clean-up kit (Roche) and either
sequenced directly or cloned into pGem-T Easy vectors
(Promega). After transformation in DH10B-cells and
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singularization of clones, plasmids were purified with the
GeneJET Plasmid Miniprep Kit (Fermentas). Sanger-based se-
quencing reactions were carried out by a commercial service
(StarSeq). Sequence reads of novel MB splice forms, such as
MB sequences derived form 5′/3′ RACE reactions were submit-
ted to the EMBL database (http://www.ebi.ac.uk/, last accessed
date on September 24, 2013).
Quantitative real-time reverse-transcriptase PCR
The qRT–PCR reactions were performed on cDNA samples
from hypoxic or normoxic MDA-MB468 and DLD-1 cells.
The primer combinations used for each qRT–PCR reaction
were chosen to specifically hybridize to only one MB splice
variant of interest (see Fig. 3; Supplementary Material, Table
S2). The Power SYBRGreen PCRMastermix (Applied Biosys-
tems) was used at a total volume of 10 ml with annealing tem-
peratures of 578C in an ABI 7500 real-time cycler (Applied
Biosystems).
For absolute quantification of samples with unknown cDNA
content, we applied the standard curve approach with serial
10-fold dilutions of standard plasmids containing a matching
amplicon as an insert. As a positive control for cellular response
tohypoxic conditions, transcripts of theVEGFAgenewerequan-
tified in hypoxic and normoxic samples (51). Triplicate assays
were measured in each run, with a total of n ¼ 3 experiments
for each amplicon assay. Average ratios and standard deviations
were calculated via Excel 2003 (Microsoft). A two-sided Stu-
dents’ t-test with an error value of 5% (a ¼ 0.05)was performed
to infer statistical significance.
Detection ofMB splice variants in cancer biopsies
MB expression was analyzed in tumor and normal adjacent
tissues obtained from surgical specimens from 21 primary
breast cancer patients. Patient material was collected at the Uni-
versity Hospital of Bonn between 2007 and 2012. The studywas
approved by the institutional review board. Matched formalin-
fixed and paraffin-embedded tissue (FFPET) and fresh-frozen
tissues from the same patients were analyzed. MB and CAIX
immunostaining of 3-mm FFPET sections was performed
using theLabVisionAutostainer 480S system (ThermoScientif-
ic). The PT-Modulewas used for dewaxing and epitope retrieval
(pH 6.0 at 998C for 20 min). The following antibodies and dilu-
tions were used: rabbit monoclonal MB antibody EP3081Y,
(Abcam, Cambridge, UK), dilution 1:150; rabbit polyclonal
CAIX antibody (Abcam), dilution 1:300.
Total RNA was isolated from the fresh-frozen tumor and
normal adjacent tissues by means of the RNAeasy Kit
(Qiagen), following the Animal Tissue protocol. As described
above, the first-strand cDNA synthesis was conducted with the
Superscript III RT- Kit (Invitrogen), but on 500 ng total RNA.
The resulting cDNA was diluted 1:4 and quantified with the
Qubit ssDNA Assay Kit (Life Technologies). qRT–PCRs were
performed as described above, with the FastStart Universal
SYBR Green Master (ROX) Mix (Roche) in duplicate assays.
Absolute copy numbers of MB transcripts per 10 ng cDNA
were determined using the standard curve approach. For
statistical correlations, parametric Pearson tests were performed
with SPSS, Version 21 (IBM SPSS Statistics). Samples were
sorted according to the overallMB level detected in the biopsied
tumors.
Functional analysis of a candidate uORF and a novelMB
promoter via dual luciferase reporter assays
To investigate the functionality of the candidate uORF and the
novel promoter, the corresponding sequence regions were amp-
lified via PCR on human genomic placenta tissue DNA and
cloned into luciferase reporter gene vectors (pGL3-control
vectors, Promega). For PCR amplification of uORF and
mutated uORF (c.-3067A . T) constructs, all forward and
reverse primers were equipped with a 5′-end HindIII and NcoI
site, respectively (Supplementary Material, Table S2).
Forward and reverse primers used for the amplification of candi-
date promoter sections were engineered to carry 5′ MluI and
HindIII recognition sites, respectively (SupplementaryMaterial,
Table S2). PCR reactions were prepared as described above.
Annealing temperatures were in accordance with the melting
temperatures of each primerset (see Supplementary Material,
Table S2). Obtained PCR products were digested with the re-
striction enzymes that matched their flanking recognition sites.
pGL3-control vectors (Promega) for cloning the uORF con-
structs and candidate promoter sections were digested with re-
spective restriction enzymes (Fermentas). All vectors were
then dephosphorylated at their 5′-ends byAntarctic Phosphatase
(NEB). PCR products were ligated into the modified vectors
using T4 ligase (Fermentas) and transformed as described
above. We also generated a negative control vector lacking the
SV40 promoter, by subjecting pGL3-control vector to a MluI/
HindIII digest (Fermentas). After dephosphorylation and
Klenow (NEB) end-filling of 5′ overhangs the blunt ended
vector was ligated with T4 ligase (Fermentas) and transformed
into bacterial host cells as described above.
About 104 MDA-MB468 cells were seeded in triplicates. By
using 0.3 ml of the FuGENE-HD Transfection Reagent
(Promega), all wells were co-transfected with 240 ng of
pGL3-based firefly luciferase plasmids and 26 ng of pGL4.74
renilla luciferase vectors (Promega) as internal controls. After
44 h, DLRAs (Promega) assessed the influence of the uORF on
the translation efficacies of theCDSand the transcriptional activ-
ity of different promoter constructs. Light signal intensity was
quantified in a Glomax 96-well luminometer (Promega), choos-
inga samplevolumeof 40 ml for both luciferin reagents.Normal-
ization of transfection efficacies was done by dividing the total
amount of luciferase light units in each pGL3 sample by the
co-transfected pGL4.74 renilla light units, yielding RLUs.
The RLU quantities of the mutated TTG (c.-3067A . T)
uORF constructs were normalized on the RLU values of the
ATG-uORF-constructs in each (n ¼ 5) trial. RLU quantities of
promoter constructs were normalized on RLUs of endfilled
control vectors for enabling signal-to noise ratio estimation.
For both, the uORF and the promoter experiments, standard
deviations were calculated via Excel 2003 (Microsoft). A two-
sidedStudent’s t-testwith anerror rateof1%(a ¼ 0.01)wasper-
formed to test for significance.
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SEQUENCE ACCESSION NUMBERS
Accession numbers of sequence reads submitted to the EMBL
database will be provided as soon as they are available.
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Supplementary Material is available at HMG online.
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SUPPLEMENTARY FIGURES 
Table S1 (A). Table of representative Hsa MB EST accessions, supporting the respective 
splice variants. Table S1 (B). Table of representative Mmu Mb EST accession numbers and 
according splice variants. 
 
Table S2. List of all primers applied. Restriction enzyme recognition sites are underlined. 
 
Figure S1 (Top). Revised organization of the human MB gene. Untranslated exons (tagged 
with a ‘u’) are shown in blue color while CDS-encoding exons (tagged with a ‘c’) are red. 
Annotation of the MB-CDS start and stop codons are included. (Below). Presence of MB 
splice variants in different tissues. For each tissue, the number of representing ESTs is 
indicated. Green: MB transcripts detected in MDA-MB468 and DLD-1 via qRT-PCR. Hashes 
indicate transcripts whose integrity has been approved by 5’-RACE reactions. On the right 
hand side of the splice variants, the corresponding NCBI-AceView annotation letters are 
written in parentheses and protein encoding splice variants are marked with a Y. The standard 
MB gene promoter of variant 2 and the additional five predicted promoter regions are 
indicated. 
 
Table S3. Conservation between human MB exons and the corresponding gene sequences 
(flanked by a 50kb frame) of other species. Displayed are hits with an e-value (E<1^-10) and 
their percent nucleotide identities. Yellow: CDS-containing exons. 
 
Figure S2 (A). Comparison of the Hsa MB and Mmu Mb gene structures. Figure S2 (B). 
(Top): Revised organization of the mouse Mb gene, exon-intron structure. The size of each 
exon is written on its top. Untranslated exons (tagged with a ‘u’) are shown in blue color 
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while CDS-encoding exons (tagged with a ‘c’) are red. Annotation of the Mb-CDS start and 
stop codons are included. (Below): Presence of mouse Mb splice variants in different tissues 
(the corresponding number of ESTs are indicated). On the right hand side of the splice 
variants, the according NCBI-AceView annotation letters are written in parentheses and 
protein encoding splice variants are marked with a Y. Predicted promomoter regions are 
indicated as green boxes. 
 
Figure S3. Repetitive elements in the human MB gene region. Exon positions are highlighted 
in blue and red. Repeats are marked as arrows, according to their class and orientation. 
 
Table S4. Datasets analyzed from the NCBI-Sequence Read Archive (SRA). Originating 
tissues are listed on the left. 
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Table S1 (A). Table of representative Hsa MB EST accessions, supporting the respective splice variants. 
Acc.No Tissue Dev. stage Variant Exon 1u 
Exon 
2u 
Exon 
3u 
Exon 
4u 
Exon 
5u 
Exon 
6u 
Exon 
7u 
Exon 
8u 
Exon 
9u 
Exon 
9c 
Exon 
10u 
Exon 
11c 
Exon 
12c 
exon size    218 bp 86 bp 103 bp 164 bp 113 bp 132bp 116 bp 225 bp 72 bp 103 bp 140 bp 223 bp 679 bp 
2938944 skeletal muscle  1           140 x  
21806536 coronary artery endothelial cells  2         x x  x x 
21828777 heart  2         66 x  x x 
21829059 heart  2         64 x  x x 
21887456 muscle  2         64 x  x x 
21887573 muscle  2         68 x  x x 
4711867 sciatic nerve  2         51 x  x x 
29149305 skeletal muscle  3         64 x +86bp  x x 
20993663 heart  4         x x  till 104 from 373 
21826735 heart  5        75  x  x x 
21827048 heart  5        71  x  x x 
16843686 liver fetal 5        71  x  x x 
2800052 prostate  5        71  x  x x 
566930 skeletal muscle  5        63  x  x x 
1490850 prostate  6        5  x  till 79 from 327 
29129213 skeletal muscle  7        31+ Intron x x  x x 
29217103 skeletal muscle  7        71+ Intron x x  x x 
29172333 skeletal muscle  8        147+79  x  x x 
4742007 large cell carcinoma cell line (lung)  9     29     x  x x 
21776299 muscle fetal 9     84     x  x x 
29148116 skeletal muscle  9     79     x  x x 
709887 total fetus 8-9weeks 12     31       x x 
3045051 adrenal cortex carcinoma cell line  13    164      x  x x 
4150768 ascites cancer cell line  13    129      x  x x 
29126033 skeletal muscle  14    116   116     x x 
599575 heart 8-10weeks 15   153         x x 
4656873 adenocarcinoma cell line  16    48+164      x  x x 
 testis2  18  93 103       x  x x 
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Table S1 (B). Table of representative Mmu Mb EST accession numbers and according splice variants. 
 
Acc.No Tissue Dev. stage Variant Exon 1u Exon 2u Exon 3u Exon short4u Exon 4u Exon 4c Exon 5u Exon 6c Exon 7c 
exon size    143 bp 85 bp 74 bp 65 bp 203 bp 105 bp 77 bp 224 bp 588 bp 
9943731 heart  1       77 x x 
7851096 diaphragm  2     194 x  x x 
26679870 eye  2     49 x  x x 
10023174 heart  2     48 x  x x 
21709940 muscle  2     5 x  x x 
7374498 diaphragm  3    34  x  x x 
10022213 heart  3    54  x  x x 
7270694 liver  3    54  x  x x 
8951593 salivary gland  3    51  x  x x 
9171407 skeletal muscle  4     41 x  till 63 from 338 
10779292 brain  5   74   x  x  
9442696 heart  6 167     x  x x 
8764040 mammary gland tumor  6 133     x  x x 
9771898 tumor gross tissue  7 45 85    x  x x 
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Table S2. List of all primers applied 
 
Name Sequence (5’ --- 3’) Application 
Ex1 for ACATTCCCAGAGAGTCTTGG 
RT-PCR 
Ex2 for GAAGCCTCCTGTTGGGTAG 
Ex3 for GCACCTGAGTTCCAAAGGAG 
Ex5 for AGGACAGCTGGGGAGAAG 
Ex8 for GCATGTTGGCCTGGTCCTTTGC 
Ex10 for GGTTGAGCGAAGGGATTGTC 
Ex9ctag for CCACCCACACCCTAAGATCA 
Ex3 rev CATCCCAGCTCCATCTCAAG 
Ex9 rev CCCAGACGTTCAGCACCAACTGCC 
Ex12 rev CATGCAGAACACAGTGAGCC 
Ex3 rev CATCCCAGCTCCATCTCAAG 
5’RACE Ex4 rev CTCACTCTCTCACCTGCTC 
Ex5 rev AGCTGTCCTCGCAGAGCCT 
Ex1/3 for CACCTGTGAATGCTTGAATTGC 3’RACE 
Ex4a for GCTAGGTACTGTAGAGCAGG qRT-PCR on MB468 and DLD-1 
Ex4b for GCATGTTGGCCTGGTCCTTTGC qRT-PCR on Matched Samples 
Ex9u for CCCAGTGAGCCCATACTTGC 
qRT-PCR on 
MB468, DLD-1 and 
Matched Samples 
Ex9/11 rev CTTAAAGAGCCTGATGAGGAC 
Ex5/9 for GAGCTGTGACTGCGCCATG 
Ex6/9 for TGTGCAGACTGCGCCATG 
Ex7/9 for GACTACAGACTGCGCCATG 
Ex11 rev GCCTTCATCTCGTCCTCTGAC 
VEGFA for AGGAGGAGGGCAGAATCATCA 
VEGFA rev CTCGATTGGATGGCAGTAGCT 
uORF-ATG for NNNNAAGCTTGGGGAGCTGTATGGAGGCTCG uORF with 
HindIII (for) and 
NcoI (rev) sites 
(underlined) 
uORF-TTG for NNNNAAGCTTGGGGAGCTGTTTGGAGGCTCG 
uORF rev NNNNCCATGGCGCAGTCTGTAGTCCCAGCTA 
+501 for NNNNACGCGTTGTCCCTGGTGTGCACTAAG 
Promoter upstream 
to exon 5u with 
MluI (for) and 
HindIII (rev) sites 
(underlined) 
+335 for NNNNACGCGTCACATCTGCTGGGAATGGGTAG 
+224 for NNNNACGCGTACTGTGGAGGCGGGGCTGGTC 
+179 for NNNNACGCGTTGGAGCTGGAGGAGCCACTC 
+108 for NNNNACGCGTGGCCACACCTGTTGACTAAGG 
-17 rev NNNNAAGCTTCACAGGGAACTAAAAATACAGTT 
-25 rev NNNNAAGCTTGGGAGAGGCACAGGGAACTAA 
-191 rev NNNNAAGCTTCAAGCTTGCTCCAGACTCCC 
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Figure S1. Revised organization of the human MB gene 
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Table S3. Conservation between human MB exons and the corresponding gene sequences 
(flanked by a 50kb frame) of other species 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* More than one sufficient (<1^-10) hit 
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Figure S2 (A). Comparison of the Hsa MB and Mmu Mb gene structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 (B). Revised organization of the mouse Mb gene 
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Figure S3. Repetitive elements of the human MB gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Datasets analyzed from the NCBI-Sequence Read Archive (SRA) 
 
Heart SRR015300 SRR015301 SRR015303 SRR015304 SRR015305 SRR015306  
Muscle SRR015307 SRR015308 SRR015309 SRR015311 SRR015312 SRR015313  
Breast SRR015270 SRR015271 SRR015272 SRR015273    
Colon SRR015314 SRR015315 SRR015316 SRR015317 SRR015318 SRR015319 SRR015320 
LNCaP SRR202054 SRR202058 SRR202059 SRR202060    
MCF7 SRR015274 SRR015275 SRR015276 SRR015277 SRR097789   
MDA-MB468 SRR097791       
DLD-1 DRR000014 DRR000015 DRR000016     
Prostate 
cancer SRR057630 SRR057643 SRR057646     
Colon cancer SRR222176 SRR222178      
 
